Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TLSA

Tiziana Life Sciences Ltd

Apr 19 • 04:00PM ET

0.6660

Dollar change +0.0260
Percentage change 4.06	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ONEQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	38.03%	Shs Outstand	194.61M	Perf Week	51.36%
Market Cap	129.61M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	120.59M	Perf Month	38.75%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.41%	Short Float	0.27%	Perf Quarter	14.20%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	3.49	Perf Half Y	-11.83%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.32M	Perf Year	-43.08%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.41 - 1.39	Perf YTD	18.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.98%	ROI	-	52W High	-52.18%	Beta	0.62
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	62.44%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	72.11	Volatility	29.87% 13.81%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.84
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	7.04%	Payout	-	Rel Volume	6.52	Prev Close	0.64
Sales Surprise	-	EPS Surprise	-2.57%	Sales Q/Q	-	Earnings	-	Avg Volume	92.36K	Price	0.67
SMA20	42.75%	SMA50	36.03%	SMA200	10.05%	Trades		Volume	602,371	Change	4.06%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-20	Initiated	B. Riley Securities	Buy	$8
Dec-17-18	Initiated	Laidlaw	Buy

Today 07:00AM	Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today (GlobeNewswire)
Apr-18-24 07:00AM	Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology (GlobeNewswire) +24.76%
Apr-11-24 07:00AM	Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology (GlobeNewswire)
Mar-05-24 07:00AM	Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease (GlobeNewswire) +9.60%
Jan-08-24 07:00AM	Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients (GlobeNewswire) -6.79%
09:30AM	Loading…
Jan-05-24 09:30AM	Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 (GlobeNewswire)
07:00AM	Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation (GlobeNewswire)
Dec-19-23 07:00AM	Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis (GlobeNewswire) +5.45%
Dec-04-23 07:09AM	Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar (GlobeNewswire)
Nov-30-23 07:00AM	Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis (GlobeNewswire)
Nov-01-23 07:00AM	Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023 (GlobeNewswire)
Oct-20-23 05:20AM	TLSA: Six Month SPMS Results (Zacks)
Oct-18-23 07:00AM	Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment (GlobeNewswire)
Oct-17-23 03:27AM	Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial (News Direct) -14.00%
Oct-16-23 07:00AM	Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab (GlobeNewswire) +6.25%
07:00AM	Loading…
Oct-13-23 07:00AM	Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) (GlobeNewswire) +8.14%
Oct-11-23 07:00AM	Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress (GlobeNewswire)
Sep-26-23 07:00AM	Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis (GlobeNewswire)
Sep-12-23 08:19AM	Tiziana Life Sciences' Alzheimer's treatment validated in new study (News Direct)
Sep-08-23 07:00AM	Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-06-23 07:00AM	Study Validating MoA of Intranasal Foralumab in Alzheimers Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance (GlobeNewswire)
Aug-28-23 07:12AM	TLSA: IND Cleared by FDA and Alzheimers Deep Dive (Zacks)
Aug-23-23 10:30AM	Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer (GlobeNewswire)
07:00AM	Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology (GlobeNewswire)
Aug-17-23 07:00AM	Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease (GlobeNewswire)
Aug-15-23 09:28AM	Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment (News Direct) +36.56%
07:00AM	Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimers Disease (GlobeNewswire)
Aug-01-23 08:00AM	Proactive Analyst expects "some good news over the next 1-2 months" from Tiziana Life Sciences (News Direct)
Jul-21-23 04:15PM	Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice (GlobeNewswire)
Jun-20-23 06:07AM	TLSA: Reduced Microglial Activation in PET Scan (Zacks Small Cap Research) +6.92%
09:02AM	Loading…
Jun-18-23 09:02AM	We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate (Simply Wall St.)
Jun-13-23 07:00AM	Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer (GlobeNewswire)
Jun-05-23 10:00AM	Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis (GlobeNewswire) -10.68%
May-25-23 07:00AM	Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) (GlobeNewswire)
May-23-23 07:00AM	Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform (GlobeNewswire)
May-17-23 07:00AM	Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17 (GlobeNewswire)
May-05-23 10:49AM	Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst (News Direct)
May-02-23 05:52AM	TLSA: SPMS Phase II to Proceed (Zacks Small Cap Research)
Apr-27-23 07:00AM	Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference (GlobeNewswire) -7.52%
Apr-26-23 02:47PM	Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update (GlobeNewswire)
Apr-24-23 07:00AM	Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire) -5.77%
Apr-21-23 10:47AM	Tiziana Life Sciences plans to file Investigational New Drug Application for Alzheimer's treatment (News Direct) -8.72%
Apr-20-23 07:00AM	Tiziana Life Sciences to File Alzheimers IND for Intranasal Foralumab in Q2 2023 (GlobeNewswire)
Apr-19-23 10:30AM	Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis (ACCESSWIRE) -9.30%
Apr-18-23 07:00AM	Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes (GlobeNewswire) +8.40%
Apr-17-23 09:00AM	Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce Tiziana Life Sciences (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise (ACCESSWIRE) +11.21%
05:53AM	Tiziana Life Sciences pursuing development of intranasal foralumab for Long COVID treatment (News Direct)
Apr-13-23 08:30AM	EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients (Benzinga) +5.88%
07:00AM	Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID (GlobeNewswire)
Apr-10-23 07:00AM	Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the Preserving the Brain Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai (GlobeNewswire)
Apr-04-23 10:43AM	Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference (GlobeNewswire) -21.17%
07:00AM	Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage (GlobeNewswire)
Mar-31-23 07:00AM	Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimers Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimers and Parkinsons Disease and Related Neurological Disorders Conference in Sweden (GlobeNewswire)
Mar-29-23 06:13AM	Tiziana Life Sciences Ltd's (NASDAQ:TLSA) market cap rose US$30m last week; retail investors who hold 51% profited and so did insiders (Simply Wall St.)
Mar-28-23 07:00AM	Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) (GlobeNewswire) +24.42%
Mar-22-23 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO (GlobeNewswire) -14.54%
Mar-21-23 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO (GlobeNewswire) +11.27%
Mar-20-23 08:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO (GlobeNewswire) +20.30%
Mar-17-23 08:10AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO (GlobeNewswire) +22.42%
07:00AM	Tiziana Life Sciences Highlighted in Forbes Article (GlobeNewswire)
06:03AM	TLSA: Foralumabs Versatile Applications (Zacks Small Cap Research)
Mar-09-23 07:05AM	Tiziana Life Sciences shares details of intranasal foralumab study published in PNAS (News Direct)
Mar-08-23 07:00AM	Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab (GlobeNewswire) +5.48%
Feb-09-23 05:24AM	Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely" (News Direct)
Jan-08-23 08:53AM	Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-04-23 07:00AM	Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer (GlobeNewswire) +8.09%
Jan-03-23 11:11AM	Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis (Benzinga)
07:00AM	Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab (GlobeNewswire)
Dec-29-22 05:00PM	Tiziana Life Sciences Ltd (Tiziana or the Company) - Updated Interim Results for the Six Months Ended 30 June 2022 (GlobeNewswire)
Dec-27-22 05:00PM	Tiziana Life Sciences Ltd (Tiziana or the Company) - Interim Results for the Six Months Ended 30 June 2022 (GlobeNewswire) -6.67%
Dec-16-22 07:00AM	Tiziana to Participate in January Investor Meetings (GlobeNewswire)
Dec-15-22 07:00AM	Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study (GlobeNewswire)
Dec-14-22 06:00AM	Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements (GlobeNewswire)
Dec-06-22 07:00AM	Tiziana Life Sciences Announces Date of Annual General Meeting 2022 (GlobeNewswire)
Dec-05-22 03:00AM	TLSA: Novembers Investor Day (Zacks Small Cap Research)
Nov-23-22 10:59AM	Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects (GlobeNewswire)
Nov-10-22 07:00AM	Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS) (GlobeNewswire) +11.29%
Nov-04-22 07:00AM	Tiziana Life Sciences to Host Investor Call (GlobeNewswire)
Nov-03-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman (GlobeNewswire)
Nov-02-22 07:00AM	Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients (GlobeNewswire)
Oct-26-22 07:00AM	Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients (GlobeNewswire)
Oct-19-22 07:00AM	Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference (GlobeNewswire)
Oct-13-22 05:46AM	TLSA: New Management Takes the Reins (Zacks Small Cap Research)
Oct-12-22 07:00AM	Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients (GlobeNewswire)
Sep-29-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer (GlobeNewswire)
Sep-28-22 07:00AM	Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the Preserving the Brain Scientific Conference and Exhibit at the Fondazione Prada in Milan (GlobeNewswire)
Sep-23-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer (GlobeNewswire)
Sep-21-22 07:30AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman (GlobeNewswire) +9.87%
Sep-20-22 06:34AM	Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab (GlobeNewswire)
Sep-16-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman (GlobeNewswire) -33.73%
Sep-15-22 07:00AM	Tiziana Life Sciences Announces Grant received by the Brigham and Womens Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis (GlobeNewswire)
Sep-09-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer (GlobeNewswire)
Aug-25-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman (GlobeNewswire) +5.96%
Aug-17-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman (GlobeNewswire)
Aug-16-22 04:24PM	Investing in Electric Vehicles and Green Transportation (Investopedia)
Aug-01-22 09:05AM	Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
08:00AM	Tiziana Life Sciences Announces Presentation at Alzheimers Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimers Disease (GlobeNewswire)
Jul-18-22 06:00AM	Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer (GlobeNewswire)
Jul-15-22 04:15PM	Tiziana Life Sciences Announces Resignation of CEO (GlobeNewswire) +6.59%
Jun-17-22 04:30PM	Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice (GlobeNewswire)

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLSA

Tiziana Life Sciences Ltd

Upgrade your FINVIZ experience